PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.01
−0.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +67.7%
- EBIT
- +65.9%
- EPS
- +95.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +99.0%
- Free cash flow
- +56.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026